Adams Asset Advisors LLC lifted its stake in Pfizer Inc. (NYSE:PFE) by 4.7% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 124,709 shares of the biopharmaceutical company’s stock after acquiring an additional 5,633 shares during the period. Adams Asset Advisors LLC’s holdings in Pfizer were worth $4,452,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Janus Henderson Group PLC grew its stake in Pfizer by 243.5% during the 2nd quarter. Janus Henderson Group PLC now owns 13,175,187 shares of the biopharmaceutical company’s stock worth $442,574,000 after buying an additional 9,339,749 shares during the last quarter. Vanguard Group Inc. grew its stake in Pfizer by 2.3% during the 2nd quarter. Vanguard Group Inc. now owns 418,639,111 shares of the biopharmaceutical company’s stock worth $14,062,088,000 after buying an additional 9,239,499 shares during the last quarter. Renaissance Technologies LLC purchased a new position in Pfizer during the 2nd quarter worth $268,389,000. Canada Pension Plan Investment Board grew its stake in Pfizer by 249.6% during the 2nd quarter. Canada Pension Plan Investment Board now owns 10,713,626 shares of the biopharmaceutical company’s stock worth $359,871,000 after buying an additional 7,649,416 shares during the last quarter. Finally, Parametric Portfolio Associates LLC grew its stake in Pfizer by 42.1% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 17,818,368 shares of the biopharmaceutical company’s stock worth $598,519,000 after buying an additional 5,281,314 shares during the last quarter. 69.74% of the stock is owned by hedge funds and other institutional investors.
Several brokerages recently weighed in on PFE. Vetr upgraded Pfizer from a “hold” rating to a “buy” rating and set a $37.98 target price on the stock in a research note on Monday. BMO Capital Markets set a $39.00 target price on Pfizer and gave the stock a “buy” rating in a research note on Monday. Morgan Stanley set a $41.00 target price on Pfizer and gave the stock a “buy” rating in a research note on Friday, January 5th. Nord/LB restated a “neutral” rating on shares of Pfizer in a research note on Tuesday, January 2nd. Finally, UBS Group set a $40.00 price target on Pfizer and gave the company a “buy” rating in a research note on Wednesday, December 6th. Two investment analysts have rated the stock with a sell rating, seven have given a hold rating and thirteen have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $38.83.
In other news, insider Alexander R. Mackenzie sold 14,700 shares of the company’s stock in a transaction dated Wednesday, November 1st. The stock was sold at an average price of $35.30, for a total value of $518,910.00. Following the sale, the insider now owns 117,432 shares in the company, valued at $4,145,349.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Rady A. Johnson sold 8,000 shares of the company’s stock in a transaction dated Friday, December 15th. The stock was sold at an average price of $37.07, for a total value of $296,560.00. Following the completion of the sale, the executive vice president now owns 46,963 shares in the company, valued at approximately $1,740,918.41. The disclosure for this sale can be found here. Insiders sold 29,450 shares of company stock worth $1,065,220 in the last 90 days. Company insiders own 0.06% of the company’s stock.
Shares of Pfizer Inc. (NYSE:PFE) traded down $0.02 on Friday, hitting $36.54. The stock had a trading volume of 19,218,988 shares, compared to its average volume of 15,820,000. Pfizer Inc. has a 1 year low of $30.90 and a 1 year high of $37.35. The company has a quick ratio of 1.15, a current ratio of 1.43 and a debt-to-equity ratio of 0.56. The stock has a market capitalization of $217,800.00, a P/E ratio of 22.42, a price-to-earnings-growth ratio of 2.46 and a beta of 1.01.
Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.67 EPS for the quarter, topping analysts’ consensus estimates of $0.65 by $0.02. Pfizer had a return on equity of 25.41% and a net margin of 18.69%. The firm had revenue of $13.17 billion for the quarter, compared to the consensus estimate of $13.17 billion. During the same quarter in the prior year, the business earned $0.61 earnings per share. The company’s revenue was up .9% compared to the same quarter last year. equities research analysts expect that Pfizer Inc. will post 2.59 EPS for the current fiscal year.
The business also recently announced a quarterly dividend, which will be paid on Thursday, March 1st. Stockholders of record on Friday, February 2nd will be paid a $0.34 dividend. This is an increase from Pfizer’s previous quarterly dividend of $0.32. The ex-dividend date is Thursday, February 1st. This represents a $1.36 dividend on an annualized basis and a dividend yield of 3.72%. Pfizer’s dividend payout ratio is presently 78.53%.
Pfizer declared that its board has authorized a share repurchase program on Monday, December 18th that allows the company to repurchase $10.00 billion in shares. This repurchase authorization allows the biopharmaceutical company to reacquire shares of its stock through open market purchases. Shares repurchase programs are often a sign that the company’s management believes its stock is undervalued.
TRADEMARK VIOLATION NOTICE: “Adams Asset Advisors LLC Has $4.45 Million Position in Pfizer Inc. (NYSE:PFE)” was first reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this news story on another site, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The original version of this news story can be viewed at https://ledgergazette.com/2018/01/13/adams-asset-advisors-llc-increases-stake-in-pfizer-inc-pfe.html.
Pfizer Company Profile
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.